Olanzapine/fluoxetine: A review of its use in the treatment of acute bipolar depression

Drugs

Volumn 68, Issue 8, 2008, Pages 1115-1137

  Deeks, Emma D ^a,b   Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis Drug Evaluations; Bipolar depression, treatment; Olanzapine fluoxetine, general

Indexed keywords

ALPRAZOLAM; CARBAMAZEPINE; CIPROFLOXACIN; CLOZAPINE; DIAZEPAM; DOPAMINE; FIBROBLAST GROWTH FACTOR 2; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; OLANZAPINE; OMEPRAZOLE; PHENYTOIN; PIMOZIDE; RIFAMPICIN; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE;

ANXIETY; AREA UNDER THE CURVE; ASTHENIA; BIPOLAR DEPRESSION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERGLYCEMIA; INCREASED APPETITE; INSOMNIA; LIPID BLOOD LEVEL; MANIA; MONOTHERAPY; NAUSEA; NERVOUSNESS; NEUROTRANSMISSION; ORTHOSTATIC HYPOTENSION; PHARMACODYNAMICS; PROLACTIN BLOOD LEVEL; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TREMOR; WEIGHT GAIN; XEROSTOMIA;

ACUTE DISEASE; BENZODIAZEPINES; BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; DRUG COMBINATIONS; DRUG INTERACTIONS; FLUOXETINE; HUMANS; QUALITY OF LIFE;

EID: 43749106879     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868080-00008     Document Type: Review

References (76)

1. World Health Organization. The world health report 2001 [online]. Available from URL: http://www.who.int/whr/2001/en/whr01_en.pdf [Accessed 2007 Oct 16]
2. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication [published erratum appears in Arch Gen Psychiatry 2005; 62 (7): 768]. Arch Gen Psychiatry 2005 Jun; 62 (6): 593-602
3. Post RM. The impact of bipolar depression. J Clin Psychiatry 2005; 66 Suppl. 5: 5-10
4. Malhi GS, Mitchell PB, Salim S. Bipolar depression: management options. CNS Drugs 2003; 17 (1): 9-25
5. Ketter TA, Nasrallah HA, Fagiolini A. Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder. Psychopharmacol Bull 2006; 39 (1): 120-46
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association, 2000: 345-428
7. McIntyre R, Katzman M. The role of atypical antipsychotics in bipolar depression and anxiety disorders. Bipolar Disord 2003; 5 Suppl. 2: 20-35
8. Simpson SG, Jamison KR. The risk of suicide in patients with bipolar disorders. J Clin Psychiatry 1999; 60 Suppl. 2: 53-6
9. Calabrese JR, Hirschfeld RMA, Reed M, et al. Impact of bipolar disorder on a U.S. community sample. J Clin Psychiatry 2003 Apr; 64 (4): 425-32
10. Calabrese JR, Hirschfeld RMA, Frye MA, et al. Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample. J Clin Psychiatry 2004 Nov; 65 (11): 1499-504
11. Judd LL, Akiskal HS, Schettler PJ, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry 2003 Mar; 60: 261-9
12. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002 Jun; 59: 530-7
13. Thase ME. Pharmacotherapy of bipolar depression: an update. Curr Psychiatry Rep 2006 Dec; 8 (6): 478-88
14. Möller HJ, Grunze H. Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci 2000; 250 (2): 57-68
15. Fountoulakis KN, Grunze H, Panagiotidis P, et al. Treatment of bipolar depression: an update. J Affect Disord. Epub 2007 Nov
16. Eli Lilly and Company. Symbyax® (olanzapine and fluoxetine HCL capsules): US prescribing information [online]. Available from URL: http://pi.lilly.com/us/symbyax-pi.pdf [Accessed 2007 Oct 17]
17. FDA. Zyprexa® (olanzapine tablets): US prescribing information [online]. Available from URL: http://www.fda.gov/ cder/foi/label/2007/ 020592s042s043,021086s022s023,s026lbl021 253.pdf [Accessed 2007 Sep 27]
18. Food and Drug Administration. Prozac® (fluoxetine capsules, USP; fluoxetine oral solution, USP; fluoxetine delayed-release capsules, USP): US prescribing information [online]. Available from URL: http://www.fda.gov/cder/ foi/label/2008/0189 36s084,020101s039,021235s011lbl.pdf [Accessed 2008 Mar 31]
19. Hurst M, Lamb HM. Fluoxetine: a review of its use in anxiety disorders and mixed anxiety and depression. CNS Drugs 2000; 14 (1): 51-80
20. Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 481-508
21. McCormack PL, Wiseman LR. Olanzapine: a review of its use in the management of bipolar I disorder. Drugs 2004; 64 (23): 2709-26
22. Bhana N, Perry CM. Olanzapine: a review of its use in the treatment of bipolar I disorder. CNS Drugs 2001; 15 (11): 871-904
23. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999 Sep; 37 (3): 177-93
24. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003 Nov; 60 (11): 1079-88
25. Brown EB, McElroy SL, Keck Jr PE, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006 Jul; 67 (7): 1025-33
26. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999; 60 Suppl. 10: 5-14
27. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998 Jul; 155 (7): 921-8
28. Yatham LN, Goldstein JM, Vieta E, et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry 2005; 66 Suppl. 5: 40-8
29. Koch S, Perry KW, Bymaster FP. Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat. Neuropharmacology 2004 Feb; 46 (2): 232-42
30. Zhang W, Perry KW, Wong DT, et al. Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex. Neuropsychopharmacology 2000 Sep; 23 (3): 250-62
31. Maragnoli ME, Fumagalli F, Gennarelli M, et al. Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol Psychiatry 2004 Jun 1; 55 (11): 1095-102
32. Charney DS. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry 1998; 59 Suppl. 14: 11-4
33. Nutt DJ. The role of dopamine and norepinephrine in depression and antidepressant treatment. J Clin Psychiatry 2006; 67 Suppl. 6: 3-8
34. Evans SJ, Choudary PV, Neal CR, et al. Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci U S A 2004 Oct 26; 101 (43): 15506-11
35. Ordway GA, Szebeni K. Effect of repeated treatment with olanzapine or olanzapine plus fluoxetine on tyrosine hydroxylase in the rat locus coeruleus. Int J Neuropsychopharmacol 2004 Sep; 7 (3): 321-7
36. Nestler EJ, McMahon A, Sabban EL, et al. Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proc Natl Acad Sci U S A 1990 Oct; 87: 7522-6
37. Vaidya VA, Duman RS. Depression: emerging insights from neurobiology. Br Med Bull 2001; 57: 61-79
38. Malberg JE. Implications of adult hippocampal neurogenesis in antidepressant action. J Psychiatry Neurosci 2004 May; 29 (3): 196-205
39. Kodama M, Fujioka T, Duman RS. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry 2004 Oct 15; 56 (8): 570-80
40. Marx CE, Shampine LJ, Khisti RT, et al. Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. Pharmacol Biochem Behav 2006 Aug; 84 (4): 609-17
41. Horowitz JM, Goyal A, Ramdeen N, et al. Characterization of fluoxetine plus olanzapine treatment in rats: a behavior, endocrine, and immediate-early gene expression analysis. Synapse 2003 Dec 15; 50 (4): 353-64
42. Gronier BS, Rasmussen K. Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex. Neurosci Lett 2003 Oct 9; 349 (3): 196-200
43. Seager MA, Huff KD, Barth VN, et al. Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity. Biol Psychiatry 2004 Jun 1; 55 (11): 1103-9
44. Seager MA, Barth VN, Phebus LA, et al. Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology 2005 Aug; 181 (1): 126-33
45. Melkersson K, Dahl M-L. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 2004; 64 (7): 701-23
46. Data on file, Eli Lilly and Company, 2008
47. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004; 64 (20): 2291-314
48. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994 Mar; 26 (3): 201-14
49. Gossen D, de Suray J-M, Vandenhende F, et al. Influence of fluoxetine on olanzapine pharmacokinetics. AAPS PharmSci 2002; 4 (2): E11
50. Kassahun K, Mattiuz E, Nyhart E, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997 Mar; 25 (1): 81-93
51. Harvey AT, Preskorn SH. Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers. J Clin Psychopharmacol 2001 Apr; 21 (2): 161-6
52. Schenker S, Bergstrom RF, Wolen RL, et al. Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther 1988 Sep; 44 (3): 353-9
53. Bergemann N, Frick A, Parzer P, et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry 2004 Mar; 37 (2): 63-8
54. Tohen M, Calabrese J, Vieta E, et al. Effect of comorbid anxiety on treatment response in bipolar depression. J Affect Disord 2007 Dec; 104 (1-3): 137-46
55. Keck Jr PE, Calabrese JR, Corya SA, et al. Olanzapine/ fluoxetine combination for rapid-cycling bipolar depression [abstract no. P29]. Acta Psychiatr Scand Suppl 2004; 110 (423): 22-3
56. Tollefson DS, Thase ME, Briggs SD, et al. Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord 2007 Sep; 9 (6): 618-27
57. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression: lack of manic induction. J Affect Disord 2005 Jul; 87 (1): 121-30
58. Shi L, Namjoshi MA, Swindle R, et al. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther 2004 Jan; 26 (1): 125-34
59. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002 Apr; 159 (4 Suppl.): 1-50
60. Suppes T, Kelly DI, Perla JM. Challenges in the management of bipolar depression. J Clin Psychiatry 2005; 66 Suppl. 5: 11-6
61. Grunze H. Reevaluating therapies for bipolar depression. J Clin Psychiatry 2005; 66 Suppl. 5: 17-25
62. Goodwin GM, for the Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association of Psychopharmacology. J Psychopharmacol 2003; 17 (2): 149-73
63. Yatham LN, Kennedy SH, O'Donovan C, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 2006 Dec; 8 (6): 721-39
64. Grunze H, Kasper S, Goodwin G, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: treatment of bipolar depression. World J Biol Psychiatry 2002 Jul; 3 (3): 15-24
65. Suppes T, Dennehy EB, Swann AC, et al. Report of the Texas consensus conference panel on medication treatment of bipolar disorder 2000. J Clin Psychiatry 2002 Apr; 63 (4): 288-99
66. GlaxoSmithKline. GlaxoSmithKline Clinical Trials Registry: lamotrigine studies [online]. Available from URL: http://ctr.gsk.co.uk/Summary/lamotrigine/ studylist.asp [Accessed 2008 Mar 14]
67. Tondo L, Isacsson G, Baldessarini RJ. Suicidal behaviour in bipolar disorder: risk and prevention. CNS Drugs 2003; 17 (7): 491-511
68. Keating GM, Robinson DM. Quetiapine: a review of its use in the treatment of bipolar depression. Drugs 2007; 67 (7): 1077-95
69. AstraZeneca. Seroquel® (quetiapine fumarate) tablets: US prescribing information [online]. Available from URL: http://www1.astrazeneca-us.com/pi/ Seroquel.pdf [Accessed 2008 Mar 31]
70. Corya SA, Perlis RH, Keck Jr PE, et al. A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression. J Clin Psychiatry 2006 May; 67 (5): 798-806
71. Brown EB, Dunner DL, Adams D, et al. Olanzapine/fluoxetine combination versus lamotrigine in the long-term treatment of bipolar I depression [abstract no. NR189]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto (ON): 78-9
72. Food and Drug Administration. Lamictal® (lamotrigine) tablets: Lamictal® (lamotrigine) chewable dispersible tablets [online]. Available from URL: http://www.fda.gov/cder/foi/label/ 2006/020241s10s21s25s26s27, 020764s3s14s18s19s20lbl.pdf [Accessed 2007 Oct 11]
73. Lin D, Mok H, Yatham LN. Polytherapy in bipolar depression. CNS Drugs 2006; 20 (1): 29-42
74. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs 2007; 21 (11): 911-36
75. European Medicines Agency. Zyprexa® : summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/Zyprexa/H-115-PI-en.pdf [Accessed 2007 Oct 31]
76. Revicki DA, Matza LS, Flood E, et al. Bipolar disorder and health-related quality of life: review of burden of disease and clinical trials. Pharmacoeconomics 2005; 23 (6): 583-94